Sorrento Therapeutics says anti-CEA CAR-T shows increased OS in trial
Sorrento Therapeutics announced the release of data from a phase 1b clinical trial administering anti-CEA CAR-T by utilizing a unique Pressure-Enabled Drug Delivery manufactured by TriSalus Life Sciences. The preliminary data for the Hepatic Immunotherapy for Metastases clinical trial results will be presented in a poster at the Society for Immunotherapy of Cancer Annual Meeting, being held November 7-11 in Washington, DC. Five patients, four pancreatic and one colorectal, with carcinoembryonic antigen-positive, unresectable stage IV adenocarcinoma with liver metastases, who had failed one or more lines of systemic chemotherapy, each received three hepatic artery infusions of Sorrento autologous anti-CEA CAR-T cells using the Hepatic Immunotherapy for Metastases method. The immunotherapy was delivered by means of PEDD technology, which overpowers the high pressure within solid tumors that limits the reach and efficacy of therapeutic agents. Two out of the four pancreatic cancer patients had no viable liver metastases by PET scan after treatment. After 12 months, one patient with stage IV pancreatic carcinoma still showed no evidence of liver metastases on PET imaging, and his primary pancreatic tumor was well-controlled. A second patient with stage IV pancreatic cancer also had no evidence of liver metastases six weeks after CAR-T/PEDD infusions. Median overall survival post-treatment is 8.3 months and the mean OS is 9.8 months to date. No patient suffered any severe adverse event related to the CAR-T infusions.